Potency & Function
Refine contact residues, ring geometry and conformational preferences to improve target recognition or the intended biological response.
Map activity-driving positions →Design • Synthesis • SAR • Exposure
Advance validated hits through focused analog design, integrated synthesis and data-guided optimization.
Build the next series around what your current lead needs: stronger activity, improved selectivity, greater stability or longer exposure.

A better next series
Lead optimization starts with a cyclic peptide that already has experimental support. CD ComputaBio connects molecular design, analog synthesis, testing and structure–activity relationship analysis to address the properties that limit its next development step.
Refine contact residues, ring geometry and conformational preferences to improve target recognition or the intended biological response.
Map activity-driving positions →Explore substitutions that distinguish the intended target from related proteins, supported by an agreed counter-target panel.
Compare target profiles →Address degradation-sensitive regions and evaluate longer-acting formats when sustained systemic exposure is a program objective.
Explore exposure strategies →Improve solubility, sample handling, ring closure or purification so the series remains practical to synthesize and test.
Connect design with chemistry →The optimization brief prioritizes the properties that matter for your application and defines which characteristics of the parent peptide should be retained.
Establish a reliable starting point
A complete molecular definition and comparable baseline measurements make each subsequent analog more informative. We review the parent peptide, experimental conditions and chemical quality before selecting an initial design matrix.
Binding, functional activity and cellular response are considered separately. Apparent potency differences can reflect assay format, sample concentration or solubility as well as chemical changes. The first campaign therefore includes the parent reference and controls that support interpretation.
The baseline review also identifies missing comparisons that could change interpretation. For example, a linker-bearing analog should be compared with the unmodified parent in the same assay, while a stability-oriented substitution should retain a direct activity measurement.
Projects can begin with a single validated hit or an existing series. When recognition still needs independent confirmation, our cyclic peptide screening and hit validation services provide the appropriate starting stage.
From substitutions to useful relationships
A focused analog panel tests explicit hypotheses. Initial scans identify sensitive positions and tolerated changes; subsequent rounds combine favorable modifications and test whether their effects remain beneficial together.
| Design dimension | Analog strategies | Question answered |
|---|---|---|
| Contact residues | Alanine scans, conservative replacements and selected side-chain changes. | Which positions drive binding or function? |
| Stereochemistry & side chains | D-residues, noncanonical building blocks and charge or volume adjustments. | Can interactions or degradation resistance improve? |
| Ring size & closure position | Residue additions or deletions and alternative cyclization sites. | Does the constraint support an active conformation? |
| Backbone chemistry | Position-specific N-methylation or suitable backbone replacements. | How do backbone changes affect conformation and properties? |
| Cyclization linkage | Appropriate disulfide, thioether or amide-linked variants. | Which connectivity balances activity, stability and synthesis? |
| Attachment positions | Linker, label or half-life-extension attachment scans. | Where can the molecule tolerate added functionality? |
Scans are chosen around the scaffold: replacing glycine, proline or a cyclization residue can alter ring geometry as well as a local contact. Such variants are interpreted as combined structural changes. Initial panels favor informative comparisons over large collections of unrelated modifications.
Cyclic peptide structure modeling can help interpret binding hypotheses, local flexibility and steric effects. Models guide analog nomination; measured results establish SAR.
Each compound is linked to its design rationale, full chemical definition and experimental record. Negative results help identify restricted positions and guide the next set of changes.
Make the hypothesis testable
Discovery-stage synthesis translates the design matrix into defined samples. Route selection considers solid-phase assembly, protection strategy, cyclization order, building-block availability and late-stage modifications.
For quantitative comparisons, chromatographic purity is considered alongside counterions, residual solvent and peptide content when these affect stock preparation. Material specifications are matched to the assay and scale, with the same reporting conventions used throughout the series.
Ring-closure behavior and purification results feed back into design. Difficult analogs may prompt alternative closure positions, coupling strategies or residue choices, with changes documented so biological comparisons remain interpretable.

Prepare agreed analogs, controls, noncanonical residues and selected linkers or lipid modifications.
Use HPLC and LC-MS for chromatographic purity and mass assessment, with supplementary characterization for connectivity or isomer questions.
Record batch identity, quantity, purity, concentration basis, stock preparation and storage conditions.
Synthesis deliverables include the agreed samples and analytical records, together with observations relevant to the next analog set or later process development.
Optimize the complete profile
Compare parent and analogs using appropriate binding, competition and functional assays. Define whether affinity, inhibitory potency, receptor response or another endpoint drives prioritization. Suitable SPR or BLI studies can complement biochemical and cellular readouts.
Assess related proteins or designated counter-targets under matched conditions. Cross-species requirements are built into the panel. For intracellular objectives, cellular activity and target engagement help connect molecular recognition with exposure in the relevant setting.
Evaluate plasma, serum or relevant protease stability alongside solubility, aggregation risk and chemical integrity. Where degradation products are characterized, the findings can direct changes to susceptible positions or linkages.
Parent references, suitable concentration ranges, repeats and consistent assay conditions support ranking. A more potent analog with poorer solubility may require another chemistry round. Our peptide developability assessment helps organize additional property questions.
A dedicated exposure module
Exposure optimization begins by identifying the relevant limitation. Proteolytic degradation, rapid clearance and administration-related behavior call for different experiments. A longer-acting format is selected around the dosing and biological objective.

Explore site-specific residue, backbone or cyclization changes informed by degradation data. Measure intact peptide over time in the relevant matrix and compare activity after modification.
Evaluate lipidation, albumin-binding motifs and suitable linkers at tolerated attachment positions. Compare solubility, albumin association and retained target activity in relevant albumin conditions.
Scope appropriate in vivo PK and bioanalysis around species, dose and route. Interpret half-life, clearance and AUC together, including free-versus-total exposure where needed.
Linker length, attachment position and binding-group chemistry can change both albumin association and target access. Species differences and assay conditions are therefore included in planning. Serum stability, albumin affinity and in vivo elimination half-life remain distinct endpoints, each supported by its corresponding experiment. Bioanalytical planning specifies whether the assay measures intact parent, a tagged species or a broader signal, so apparent persistence can be interpreted against the molecular form of interest.
A published chemistry-to-exposure example
A published study optimized peptide–fatty acid albumin-binding tags through iterative substitutions and binding measurements, then attached an evolved tag to bioactive bicyclic peptides. The work connects sequence changes, synthesis and downstream characterization within an experimental optimization program.1

This literature example supports the design logic for testing attachment chemistry and albumin association. The choice of modification, experimental system and success criteria is defined for each lead series.
A repeatable optimization cycle
Each round ends with an explicit decision: combine a beneficial change, investigate an inconsistent result, redirect the chemistry or advance a defined series. Candidate count and iteration depth follow the learning objective.
Review parent structure, material and data.
Output: goals and reference profile.Build the analog and assay matrices.
Output: nominated chemistry set.Synthesize, cyclize and characterize.
Output: qualified test samples.Measure activity and selected properties.
Output: comparable assay results.Integrate SAR and prioritize changes.
Output: next round or lead series.Ranking combines the agreed biological endpoint with selectivity, stability, solubility, chemical quality and synthesis behavior. Closely related analogs are compared directly where informative. Design rationale, assay conditions and unresolved questions remain visible in the final recommendations.
Modular work packages
A / FOCUSED
For a validated hit needing position-level understanding. Combine a focused scan with synthesis and selected assays to identify sensitive residues and modification-tolerant regions.
Primary decision: where to optimize next.B / INTEGRATED
For a series with several linked performance gaps. Coordinate design, synthesis, activity and property testing through agreed review points and experimental iterations.
Primary decision: which series merits advancement.C / EXPOSURE
For an active series requiring improved stability or systemic exposure. Compare suitable long-acting modifications and connect their biological profile with staged PK studies.
Primary decision: which modified format to develop.The proposal defines analog numbers, synthesis quantity and purity, assay panels, iteration rounds and any PK scope before work begins.
Every compound connected to its evidence
Parent profile, prioritized limitations, design hypotheses and the agreed comparison criteria.
Full structures, stereochemistry, linkage definitions, modification positions and design rationale.
Contracted analog materials, batch details, chromatograms, mass data and relevant supplementary characterization.
Agreed binding, functional, selectivity, stability or exposure data with conditions and controls.
Structure–activity and property comparisons, parent benchmarks and multi-parameter prioritization.
Proposed changes, remaining evidence gaps and a practical path to further optimization or follow-up studies.
For programs starting without an established peptide, explore AI-guided de novo design. For an oral development objective, continue into our oral cyclic peptide discovery services for permeability, intestinal stability and oral-exposure planning.
Planning your next round
Share the full chemical structure, existing activity results, assay conditions and the property you want to improve. Available sample and analytical records help establish the baseline.
Yes. Leads from internal screens, external providers or computational programs can be reviewed. The initial plan reflects how well the current activity and molecular identity are supported.
Yes. The campaign can connect analog design, sample preparation, characterization and agreed assays. Each round is organized around an explicit comparison and decision.
Noncanonical residues, stereochemistry and closure strategies can be evaluated against the parent scaffold, available chemistry and the biological hypothesis.
We examine SAR, data consistency and the agreed property priorities, then nominate changes that test the most useful remaining hypotheses.
Yes. Stability assessment, long-acting analog design and PK confirmation can be staged according to the lead profile, intended route and exposure objective.
Turn your current lead into the next experiment
Send the complete structure, supporting data, main performance gap and intended application. We will help define a focused design, synthesis and testing plan.
Share structures and supporting files at contact@computabio.com.
Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk